Fish acute toxicity testing is used to inform environmental hazard assessment of chemicals. In silico and in vitro approaches have the potential to reduce the number of fish used in testing and increase the efficiency of generating data for assessing ecological hazards. Here, two in vitro bioactivity assays were adapted for use in high-throughput chemical screening. First, a miniaturized version of the Organisation for Economic Co-operation and Development (OECD) test guideline 249 plate reader-based acute toxicity assay in RTgill-W1 cells was developed. Second, the Cell Painting (CP) assay was adapted for use in RTgill-W1 cells along with an imaging-based cell viability assay. Then, 225 chemicals were tested in each assay. Potencies and bioactivity calls from the plate reader and imaging-based cell viability assays were comparable. The CP assay was more sensitive than either cell viability assay in that it detected a larger number of chemicals as bioactive, and phenotype altering concentrations (PACs) were lower than concentrations that decreased cell viability. An in vitro disposition (IVD) model that accounted for sorption of chemicals to plastic and cells over time was applied to predict freely dissolved PACs and compared with in vivo fish toxicity data. Adjustment of PACs using IVD modeling improved concordance of in vitro bioactivity and in vivo toxicity data. For the 65 chemicals where comparison of in vitro and in vivo values was possible, 59% of adjusted in vitro PACs were within one order of magnitude of in vivo toxicity lethal concentrations for 50% of test organisms. In vitro PACs were protective for 73% of chemicals. This combination of in vitro and in silico approaches has the potential to reduce or replace the use of fish for in vivo toxicity testing.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/etojnl/vgae083 | DOI Listing |
Blood
March 2025
Sungkyunkwan university school of medicine, Samsung Medical Center, Seoul, Korea, Republic of.
This study aimed to assess the efficacy and safety of combining cemiplimab, an anti-PD1 antibody, with isatuximab, an anti-CD38 antibody, in relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). The hypothesis was that CD38 blockade could enhance the antitumor activity of PD1 inhibitors. Eligible patients received cemiplimab (250 mg on days 1 and 15) and isatuximab (10 mg/kg on days 2 and 16) intravenously every four weeks for six cycles.
View Article and Find Full Text PDFACS Nano
March 2025
School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, P. R. China.
Mesenchymal stromal cell (MSC) therapy holds great promise for treating myocardial infarction (MI). However, the inflammatory and reactive oxygen species (ROS)-rich environment in infarcted myocardium challenges MSC survival, limiting its therapeutic impact. In this study, we demonstrate that chemical modification of MSCs with anti-VCAM1 and polydopamine (PD) significantly enhances MSC survival and promotes cardiac repair.
View Article and Find Full Text PDFEur J Cardiothorac Surg
March 2025
Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, ; Taipei City, Taiwan.
Objectives: To assess the prognostic impact of adequate lymphadenectomy and determine the optimal nodal assessment for different clinical stages of lung cancer.
Methods: We retrospectively reviewed 1214 patients with clinical stage I-III non-small cell lung cancer who had preoperative PET/CT and curative surgery (2006-2017). Patients were categorized based on whether they had adequate [R0] or inadequate lymphadenectomy [R(un)].
J Immunol
January 2025
Division of Infectious Diseases, Center for Inflammation and Tolerance, Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Organ transplant recipients require continual immune-suppressive therapies to sustain allograft acceptance. Although medication nonadherence is a major cause of rejection, the mechanisms responsible for graft loss in this clinically relevant context among individuals with preceding graft acceptance remain uncertain. Here, we demonstrate that skin allograft acceptance in mice maintained with clinically relevant immune-suppressive therapies, tacrolimus and mycophenolate, sensitizes hypofunctional PD1hi graft-specific CD8+ T cells.
View Article and Find Full Text PDFEur J Cardiothorac Surg
March 2025
Department of Cardiothoracic Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY 525 E 68 St, M-404, New York, NY 10065, USA.
Objectives: Compare oncologic outcomes between single-segment and multi-segment resections in patients with clinical stage IA1 and IA2 non-small cell lung cancer.
Methods: A retrospective review (2011-2022) was conducted using a prospectively maintained database. Patients undergoing anatomical segmentectomy for clinical stage IA ≤ 2 cm non-small cell lung cancers were included.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!